性别对根治术后上尿路与膀胱尿路上皮癌结局的差异影响:系统综述与荟萃分析
该系统综述与荟萃分析检索4个数据库,纳入66项膀胱尿路上皮癌研究(100,389例)和40项上尿路尿路上皮癌研究(39,759例),比较男女根治术后生存结局。女性膀胱尿路上皮癌患者癌症特异性生存(汇总HR 1.20,95%CI 1.10-1.31)、总生存(汇总HR 1.03,95%CI 1.01-1.05)和无复发生存(汇总HR 1.13,95%CI 1.02-1.25)均更差;上尿路尿路上皮癌则无此关联。
要点
- 女性膀胱尿路上皮癌根治术后癌症特异性、总生存和无复发生存均更差。
- 上尿路尿路上皮癌根治术后男女生存结局无显著差异。
- 性别差异可能为膀胱尿路上皮癌临床决策提供参考。
核心结论
- 性别与膀胱尿路上皮癌的癌症特异性死亡、总死亡和疾病复发相关,但与上尿路尿路上皮癌无关。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Web of Science、Cochrane Library和Scopus数据库(2019年7月),遵循PRISMA声明。
- 纳入66项膀胱尿路上皮癌研究共100,389例患者,40项上尿路尿路上皮癌研究共39,759例患者。
主要发现
- 女性膀胱尿路上皮癌患者癌症特异性生存更差(汇总HR 1.20,95%CI 1.10-1.31)。
- 女性膀胱尿路上皮癌患者总生存更差(汇总HR 1.03,95%CI 1.01-1.05)。
- 女性膀胱尿路上皮癌患者无复发生存更差(汇总HR 1.13,95%CI 1.02-1.25)。
- 上尿路尿路上皮癌患者癌症特异性生存无显著性别差异(汇总HR 0.94,95%CI 0.89-1.00)。
- 上尿路尿路上皮癌患者总生存(汇总HR 0.98,95%CI 0.95-1.01)和无复发生存(汇总HR 0.90,95%CI 0.78-1.03)无显著性别差异。
临床怎么用
- 根治性膀胱切除术后女性膀胱尿路上皮癌患者预后更差,临床决策中可考虑性别因素。
- 上尿路尿路上皮癌根治术后性别不作为预后分层依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We assessed the prognostic value of sex differences in upper tract urothelial carcinoma and urothelial carcinoma of the bladder treated with radical surgery. MATERIALS AND METHODS: The PubMed®, Web of Science®, Cochrane Library and Scopus® databases were searched in July 2019 according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Studies were deemed eligible if they compared overall, cancer specific, and recurrence-free survival in patients with upper tract urothelial carcinoma and urothelial carcinoma of the bladder. Formal meta-analyses were performed for these outcomes according to sex differences. RESULTS: Overall 66 studies with 100,389 patients with urothelial carcinoma of the bladder and 40 studies with 39,759 patients with upper tract urothelial carcinoma were eligible for review and meta-analysis. Female patients with urothelial carcinoma of the bladder were associated with worse cancer specific survival (pooled HR 1.20, 95% CI 1.10-1.31), overall survival (pooled HR 1.03, 95% CI 1.01-1.05) and recurrence-free survival (pooled HR 1.13, 95% CI 1.02-1.25). In contrast, those with upper tract urothelial carcinoma were not associated with cancer specific survival (pooled HR 0.94, 95% CI 0.89-1.00), overall survival (pooled HR 0.98, 95% CI 0.95-1.01) and recurrence-free survival (pooled HR 0.90, 95% CI 0.78-1.03). CONCLUSIONS: Sex is associated with cancer specific mortality, overall mortality and disease recurrence in urothelial carcinoma of the bladder but not in upper tract urothelial carcinoma. Given the genetic and social differences between the sexes, sex differences may represent a key factor in the clinical decision making process.
引用
- Mori K, Mostafaei H, Enikeev DV, et al. Differential Effect of Sex on Outcomes after Radical Surgery for Upper Tract and Bladder Urothelial Carcinoma: A Systematic Review and Meta-Analysis. J Urol. 2020. PMID: 31995432. doi:10.1097/JU.0000000000000788
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。